These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 23136224

  • 1. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, Okada M.
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [Abstract] [Full Text] [Related]

  • 2. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T.
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW.
    PLoS One; 2020 Jan; 15(2):e0229299. PubMed ID: 32069313
    [Abstract] [Full Text] [Related]

  • 4. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
    Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, Nowak AK.
    Lung Cancer; 2015 Oct 20; 90(1):55-60. PubMed ID: 26259878
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals.
    Bille A, Belcher E, Raubenheimer H, Landau D, Cane P, Spicer J, Lang-Lazdunski L.
    Gen Thorac Cardiovasc Surg; 2012 May 20; 60(5):289-96. PubMed ID: 22453539
    [Abstract] [Full Text] [Related]

  • 10. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V, Roca E, Lucchini S, Laroumagne S, Loundou A, Dutau H, Maldonado F, Astoul P.
    Respiration; 2015 May 20; 89(6):558-64. PubMed ID: 25966972
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G, Moretti A, Piciucchi S, Tiseo M, Bersanelli M, Scarlattei M, Scarpi E, Dubini A, Matteucci F, Sanna S.
    Technol Cancer Res Treat; 2012 Apr 20; 11(2):163-7. PubMed ID: 22335410
    [Abstract] [Full Text] [Related]

  • 12. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
    Pilling J, Dartnell JA, Lang-Lazdunski L.
    Thorac Cardiovasc Surg; 2010 Jun 20; 58(4):215-9. PubMed ID: 20514576
    [Abstract] [Full Text] [Related]

  • 13. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y, Yui M, Aoyagi K, Kishida Y, Seki S, Koyama H, Yoshikawa T.
    AJR Am J Roentgenol; 2019 Feb 20; 212(2):311-319. PubMed ID: 30512992
    [Abstract] [Full Text] [Related]

  • 14. Histology of the pleural rind at [18F]FDG PET/CT hot and cold spots in mesothelioma patients after talc pleurodesis and neoadjuvant chemotherapy.
    Soltermann A, Opitz I, Burger IA.
    Pathol Res Pract; 2021 Dec 20; 228():153660. PubMed ID: 34749212
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
    Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJ.
    Eur J Nucl Med Mol Imaging; 2014 Feb 20; 41(2):276-82. PubMed ID: 24057459
    [Abstract] [Full Text] [Related]

  • 18. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S, Zahid I, Routledge T, Scarci M.
    Interact Cardiovasc Thorac Surg; 2011 May 20; 12(5):806-11. PubMed ID: 21266493
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
    Niccoli Asabella A, Di Palo A, Altini C, Fanelli M, Ferrari C, Lavelli V, Ranieri G, Gadaleta CD, Rubini G.
    Hell J Nucl Med; 2018 May 20; 21(3):191-197. PubMed ID: 30411729
    [Abstract] [Full Text] [Related]

  • 20. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
    Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.
    Cancer Med; 2017 Oct 20; 6(10):2287-2296. PubMed ID: 28941158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.